Eli Lilly (LLY) Offering Possible 14.55% Return Over the Next 29 Calendar Days

view original post

Eli Lilly’s most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $270.00 short call and a strike $290.00 long call offers a potential 14.55% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $270.00 by expiration. The full premium credit of $2.54 would be kept by the premium seller. The risk of $17.46 would be incurred if the stock rose above the $290.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.

The RSI indicator is at 57.09 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Could Eli Lilly Leapfrog Biogen in This Market?
Wed, 17 Nov 2021 11:46:00 +0000
Biotech giant Biogen (NASDAQ: BIIB) shocked the investing world earlier this year when it earned regulatory approval for its Alzheimer’s disease (AD) drug, Aduhelm. First, a panel of independent experts convened by the U.S. Food and Drug Administration (FDA) in November 2020 had strongly voted against approving the medicine, and the agency rarely goes against the wishes of these committees. Second, Aduhelm works by reducing the buildup of a harmful protein called beta-amyloid.

Glaxo (GSK), Vir Intramuscular Sotrovimab Meets Study Endpoint
Mon, 15 Nov 2021 15:27:03 +0000
Glaxo (GSK) and Vir announce non-inferiority of intramuscular administration of sotrovimab compared to intravenous administration in reducing hospitalization or death as an early treatment of mild-to-moderate COVID-19.

These Are The 5 Best Stocks To Buy And Watch Now
Sun, 14 Nov 2021 16:20:04 +0000
Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?

Google, Tesla Rival XPeng Lead 5 Stocks Near Buy Zones
Sat, 13 Nov 2021 13:34:54 +0000
Google stock and Tesla China EV rival XPeng lead an economically diverse group, three of which have cup-with-handle buy points.

How IBD Stock Of The Day Eli Lilly Is Taking On Biogen In Alzheimer’s
Fri, 12 Nov 2021 21:46:59 +0000
Eli Lilly stock is the IBD Stock Of The Day as froth lifts Alzheimer’s names, including rivals like Biogen and Cassava Sciences.

Be Sociable, Share!

Related Posts